Aktienanalyse zu Zenas Biopharma Inc (ZBIO)ZBIOZenas Biopharma Inc

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on development and commercialization of therapies for patients living with autoimmune diseases. It is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, its lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcgRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. Orelabrutinib is a highly selective central nervous system (CNS)-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib's mechanism of action targets pathogenic B cells not only in periphery but also within CNS. Its earlier stage programs include ZB021, an oral small molecule IL-17AA/AF inhibitor; ZB022, a preclinical, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcgRIIb monoclonal antibody. It operates in the Healthcare sector.

Zenas Biopharma Inc is a good buy right now due to its current price of $26.87, which is significantly below the analyst price target of $48 from Citi, indicating a potential upside of 78%. Additionally, the stock has recently shown a positive 5-day change of +8.17%, suggesting a recovery trend. However, investors should be cautious of the high net loss of $111,456,000 reported in Q2 2026, which presents a risk to the company's financial stability.